This resource aims to provide an overview of select drug checking services in Canada that are harmonizing research protocols and approaches for the purpose of ensuring nationwide comparability of collected evidence.

For the sixth consecutive year, a side event was held at the 61st Session of the Commission on Narcotic Drugs (CND) to continue the global discussion on reprioritizing the objectives and indicators used to evaluate drug policies.

Recommendations from a meeting of over 200 policymakers, public health officials, law enforcement professionals, researchers, people who use drugs, and community organizers provides an innovative roadmap to improve Canada’s policy response to illegal drugs over the coming ten years.

With growing international attention on the impacts and broad potential of drug checking services, a number of events at HR17 featured research findings and frontline experience with this harm reduction intervention.

Side event held at the 60th Commission on Narcotic Drugs offers insights into how drug policy indicators could aid in achieving the sustainable development agenda.

Collaboration between leading international scientific body and Canada’s premiere academic institution on global policy issues outlines four scenarios for how national governments could respond to questions of treaty compliance raised by their pursuit of domestic reform of cannabis policies.

The International Centre for Science in Drug Policy strongly supports Health Canada’s decision to once again allow doctors to prescribe pharmaceutical-grade heroin for the treatment of individuals with severe opioid addiction.

Overcoming my addiction to heroin as a teenager was the most challenging thing I have ever done, but a national drug policy that didn’t put health first only made it more difficult.

Research from leading international scientific body finds that compulsory treatment for addiction does not lead to better outcomes than non-mandatory methods.

On January 21, 2016, more than eighty representatives from Member States, UN agencies, and civil society organizations gathered for the launch of a scientific open letter on the path forward for drug policy evaluation.